Respiratory Research (Jan 2019)

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

M. T. Driessen,
J. Whalen,
B. Seewoodharry Buguth,
L. A. Vallejo-Aparicio,
I. P. Naya,
Y. Asukai,
B. Alcázar-Navarrete,
M. Miravitlles,
F. García-Río,
N. A. Risebrough

Affiliations

M. T. Driessen: Value Evidence and Outcomes, GSK
J. Whalen: ICON Health Economics, ICON plc
B. Seewoodharry Buguth: ICON Health Economics, ICON plc
L. A. Vallejo-Aparicio: Departamento de Evaluación de Medicamentos, GSK
I. P. Naya: Global Respiratory Franchise, GSK
Y. Asukai: Value Evidence and Outcomes, GSK
B. Alcázar-Navarrete: Hospital de Alta Resolución de Loja
M. Miravitlles: Pneumology Department, Hospital Universitari Vall d’Hebron
F. García-Río: Hospital Universitario La Paz-IdiPAZ
N. A. Risebrough: ICON Health Economics, ICON

DOI: https://doi.org/10.1186/s12931-019-0985-2
Journal volume & issue: Vol. 20, no. 1
pp. 1 – 1

Abstract

Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.

Published in Respiratory Research

ISSN: 1465-9921 (Print); 1465-993X (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://respiratory-research.biomedcentral.com/

About the journal